Login / Signup

A Comparative Study of Montelukast and Azelastine add on Therapy in Moderate to Severe Allergic Rhinitis Treatment: A Double-Blind Randomized Clinical Trial.

Hossein EsmaeilzadehNasrin Mortazavi FarSeyed Hesamedin NabavizadehMasroor BabaeianMaryam HadipourSoheila Alyasin
Published in: American journal of rhinology & allergy (2022)
Based on our findings, we recommend Azelastine in conjunction with an intranasal corticosteroid for the treatment of moderate to severe allergic rhinitis. In moderate to severe AR or even asthma management, Montelukast has no greater impact than INCS.
Keyphrases
  • allergic rhinitis
  • high intensity
  • early onset
  • chronic obstructive pulmonary disease
  • combination therapy
  • clinical trial
  • stem cells
  • bone marrow
  • cystic fibrosis
  • double blind